The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type

Janssen (J&J Innovative Medicine)

Status and phase

Completed

Phase 4

Conditions

Alzheimer Disease

Treatments

Drug: galantamine hydrobromide

Study type

Interventional

Funder types

Industry

Identifiers

NCT00216515

CR005047

Details and patient eligibility

About

The purpose of this study is to assess the efficacy of galantamine on the attention of patients with Alzheimer's Disease, how an improvement of attention of Alzheimer's Disease patients affects their activities of daily living, and the global benefit of galantamine.

Full description

Recent studies suggest that an attention deficit occurs at early stage of Alzheimer's disease and affects patients' activities of daily living. In other words, some patients without language or visuospatial dysfunction have severe impairment of activities of daily living, which might result from attention deficit. Another recent clinical study showed that galantamine is more effective in attention and vigilance of Alzheimer's disease patients than donepezil. The study hypothesis is that galantamine will improve attention and frontal executive function in Alzheimer's disease patients and is well-tolerated. 8 mg/day for the first 4 weeks, 16 mg for the next 8 weeks

Enrollment

102 patients

Sex

All

Ages

50+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female patients aged 50 years or older
Alzheimer's disease according to the criteria of DSM-IV15, NINCDS-ADRDA16
Measuring standard MMSE-K 10 to 26
Patients who are literate
Dementia patients being nursed by the family
Patients who submitted written consent before entering into the clinical trial (the guardian consent is also effective)

Exclusion criteria

If the patient was taking AChEI (Tacrine, Donepezil, Rivastigmine) to treat dementia, the patient can enter into this clinical trial as long as he/she has not taken the drug within 15 days of the beginning of the clinical trial
Neurodegenerative diseases (e.g. Parkinson's disease, Pick's disease, Huntington's disease, Down syndrome)
Dementia related to head trauma and dementia related to brain damage due to cerebral hypoxia (hypoxic brain damage after cardiopulmonary resuscitation, hypoxic brain damage after surgery, hypoxic brain damage due to addiction, hypoxic brain damage due to shock)
brain tumor, nerve syphilis, meningitis, encephalitis, brain tumor
amentia
epilepsy
major psychiatric patients such as major depression and schizophrenia
treatment-resistant gastric and peptic ulcer
patients with clinically serious hepatic, renal, lung, endocrinal or metabolic disease(thyroid, parathyroid, pituitary, renal failure, diabetes mellitus)
patients complaining of severe difficulty in urination
patients who have undergone heart surgery within 6 months or patients who experienced myocardial infarction, patients with untreated congestive heart failure, patients with severe disorders in the mitral valve or aortic valve
patients who have once taken the investigational drugs within the past 1 month from the beginning day of the clinical trial
patients with uncontrolled diabetes mellitus (if the patient is taking medication and consults the doctor on a regular basis, he/she can participate in this clinical trial)
patients who experienced hypersensitivity or allergy by a cholinesterase inhibitor
patients who have not given their consent to the clinical trial, patients who are judged inappropriate to participate in this clinical trial by the investigator